TY - JOUR
T1 - Cognitive deficits in rats after forebrain cholinergic depletion are reversed by a novel NO mimetic nitrate ester
AU - Bennett, Brian M.
AU - Reynolds, James N.
AU - Prusky, Glen T.
AU - Douglas, Robert M.
AU - Sutherland, Robert J.
AU - Thatcher, Gregory R.J.
N1 - Funding Information:
We thank Dr Khem Jhamandas for helpful discussions and critical reading of the manuscript. Mrs Diane Anderson, Ms Margo Poklewska-Koziel, and Neuroinvestigations Inc., Lethbridge, Alberta are thanked for technical assistance. Financial support for this project was provided by GB Therapeutics Ltd, Mississauga Ontario, The Institute for the Study of Aging (to GRJT), and The Heart and Stroke Foundation of Ontario (Grant T-5162 to BMB). RJS is an Alberta Heritage Medical Scientist.
PY - 2007/3
Y1 - 2007/3
N2 - Many conditions adversely affecting learning, memory, and cognition are associated with reductions in forebrain acetylcholine (ACh), most notably aging and Alzheimer's disease. In the current study, we demonstrate that bilateral depletion of neocortical and hippocampal ACh in rats produces deficits in a spatial learning task and in a recently described, delayed visual matching-to-sample task. Oral administration of the novel nitrate, GT1061 (4-methyl-5-(2-nitroxyethyl) thiazole HCl), and the acetylcholinesterase inhibitor, donepezil, reversed the cognitive deficits in both memory tasks in a dose-dependent manner. GT1061 was superior in the delayed matching-tosample task. GT1061 was absorbed rapidly after oral administration, crossed the blood brain barrier, and achieved brain concentrations that were slightly higher than those found in plasma. The activity of GT1061 was NO mimetic: soluble guanylyl cyclase (sGC) was activated, but selectivity was observed for sGC in the hippocampus relative to the vasculature; and hippocampal levels of phosphorylated ERK1/2, which is a postulated intermediary in the formation of long-term memory, were increased. The beneficial effect on visual and spatial memory task performance supports the concept that stimulating the NO/sGC/cGMP signal transduction system can provide new, effective treatments for cognitive disorders. This approach may be superior to that of current drugs that attempt only to salvage the residual function of damaged cholinergic neurons.
AB - Many conditions adversely affecting learning, memory, and cognition are associated with reductions in forebrain acetylcholine (ACh), most notably aging and Alzheimer's disease. In the current study, we demonstrate that bilateral depletion of neocortical and hippocampal ACh in rats produces deficits in a spatial learning task and in a recently described, delayed visual matching-to-sample task. Oral administration of the novel nitrate, GT1061 (4-methyl-5-(2-nitroxyethyl) thiazole HCl), and the acetylcholinesterase inhibitor, donepezil, reversed the cognitive deficits in both memory tasks in a dose-dependent manner. GT1061 was superior in the delayed matching-tosample task. GT1061 was absorbed rapidly after oral administration, crossed the blood brain barrier, and achieved brain concentrations that were slightly higher than those found in plasma. The activity of GT1061 was NO mimetic: soluble guanylyl cyclase (sGC) was activated, but selectivity was observed for sGC in the hippocampus relative to the vasculature; and hippocampal levels of phosphorylated ERK1/2, which is a postulated intermediary in the formation of long-term memory, were increased. The beneficial effect on visual and spatial memory task performance supports the concept that stimulating the NO/sGC/cGMP signal transduction system can provide new, effective treatments for cognitive disorders. This approach may be superior to that of current drugs that attempt only to salvage the residual function of damaged cholinergic neurons.
KW - Alzheimer's disease
KW - cGMP
KW - Cognition
KW - ERK
KW - Memory
KW - Nitric oxide
UR - http://www.scopus.com/inward/record.url?scp=33847031370&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33847031370&partnerID=8YFLogxK
U2 - 10.1038/sj.npp.1301054
DO - 10.1038/sj.npp.1301054
M3 - Article
C2 - 16525416
AN - SCOPUS:33847031370
VL - 32
SP - 505
EP - 513
JO - Neuropsychopharmacology
JF - Neuropsychopharmacology
SN - 0893-133X
IS - 3
ER -